Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
AstraZeneca
Dow
Baxter
Moodys

Last Updated: November 12, 2019

DrugPatentWatch Database Preview

Litigation Details for Eisai Co., Ltd. v. Teva Pharm. USA (S.D.N.Y. )

See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in Eisai Co., Ltd. v. Teva Pharm. USA
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .

Details for Eisai Co., Ltd. v. Teva Pharm. USA (S.D.N.Y. )

Date Filed Document No. Description Snippet Link To Document
2006-10-06 51 of The Patent-in-Suit Eisai, a pharmaceutical company, owns U.S. Patent No. 5,045,552 (“’552 …552 patent”), the patent-in-suit. The ’552 patent claims, among other things, the chemical compound rabeprazole…by their final patent numbers only, as the ’552 patent application and the ’013 patent application respectively…application to issue as patent ’552. (’552 Patent File History, DRLRAB 473.) The patent’s file history does…5,708,013 (“’013 patent”). (‘013 Patent File History, DRLRAB 2281.) The ’013 patent application listed the same External link to document
2006-10-06 52 collectively, “Eisai”), ask that U.S. Patent No. 5,045,552 (“’552 patent”), claiming inter alia the gastric-acid-inhibiting…in this patent-infringement action move for summary judgment of the validity of their patent against …European Patent 174,726, claiming, inter alia, the ulcer-treatment compound lansoprazole (“’726 patent”); …; Junggren’s U.S. Patent No. 4,255,431 (“’431 patent”), claiming, inter alia, the compound omeprazole…the three items cited by Teva, the ’726 patent, the ’431 patent, and the Brandstrom article; and that lansoprazole External link to document
2007-05-11 89 the Junggren patents covering omeprazole, U.S. Patent Nos. 4,337,257, 4,255,431 and 4,508,905. …series of patent applications that ultimately issued as U.S. Patent 5,708,013 (“the ’013 patent”). These…of the Junggren patent, which patent application Eisai had disclosed to the ’552 patent examiner as prior…conduct before the U.S. Patent and Trademark Office (“PTO”) in prosecuting the patent. The case having been… in this action regarding U.S. Patent No. 5,045,552 (“the ’552 patent”). This Court has jurisdiction External link to document
2007-05-14 90 the Junggren patents covering omeprazole, U.S. Patent Nos. 4,337,257, 4,255,431 and 4,508,905. …series of patent applications that ultimately issued as U.S. Patent 5,708,013 (“the ’013 patent”). These…of the Junggren patent, which patent application Eisai had disclosed to the ’552 patent examiner as prior…conduct before the U.S. Patent and Trademark Office (“PTO”) in prosecuting the patent. The case having been… in this action regarding U.S. Patent No. 5,045,552 (“the ’552 patent”). This Court has jurisdiction External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Mallinckrodt
Dow
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.